[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematopoietic-and-lymphatic-system-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematopoietic-and-lymphatic-system-neoplasm":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,67,0,25,[9,41,66,99,119,139,149,170,189,210,231,250,268,285,306,324,340,367,385,403,425,447,465,492,510],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100053584","phase-1-biomarker-guided-ruxolitinib-for-the-prevention-of-chronic-graft-versus-host-disease-after-allogeneic-hematopoietic-cell-transplantation-100053584",false,"NCT07025538","Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation","Biomarker-Guided Feasibility\u002FEfficacy Trial of Ruxolitinib in Patients With High-Risk of Chronic Graft-Versus-Host Disease Development After Allogeneic Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* PRE-SCREENING: Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* PRE-SCREENING: Agreement to allow the use of archival tissue from diagnostic tumor biopsies\n\n  * If unavailable, exceptions may be granted with study principal investigator (PI) approval\n* PRE-SCREENING: Age: ≥ 18 years\n* PRE-SCREENING: Karnofsky performance status ≥ 80\n* PRE-SCREENING: Patients must have undergone allogeneic hematopoietic cell transplantation with peripheral blood stem cells as graft source. Note: Patients receiving manipulated graft are not included\n* PRE-SCREENING: Morphologic remission per day +30 bone marrow\n* PRE-SCREENING: Any conditioning regimen (myeloablative, reduce intensity\u002Fnon-myeloablative conditioning) is allowed\n* PRE-SCREENING: Any GVHD prophylaxis (tacrolimus-sirolimus, tacrolimus-methotrexate, or post-transplant cyclophosphamide) is allowed\n* PRE-SCREENING: Life expectancy of more than 6 months\n* PRE-SCREENING: Absolute neutrophil count (ANC) \\> 1000\u002Fmm\\^3 (to be performed between day +70 and +100 after HCT unless otherwise stated)\n* PRE-SCREENING: Hemoglobin ≥ 8.0 gm\u002FdL (to be performed between day +70 and +100 after HCT unless otherwise stated)\n* PRE-SCREENING: Platelets ≥ 50,000\u002Fmm\\^3 (to be performed between day +70 and +100 after HCT unless otherwise stated)\n\n  * Note: Patients with lower counts can enroll if infection cytomegalovirus (CMV)\u002Fhuman herpesvirus 6 (HHV6), etc. is being treated actively\n* PRE-SCREENING: Total bilirubin ≤ 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease) (to be performed between day +70 and +100 after HCT unless otherwise stated)\n* PRE-SCREENING: Aspartate aminotransferase (AST) =\\\u003C 3.0 x ULN (to be performed between day +70 and +100 after HCT unless otherwise stated)\n* PRE-SCREENING: Alanine aminotransferase (ALT) =\\\u003C 3.0 x ULN (to be performed between day +70 and +100 after HCT unless otherwise stated)\n* PRE-SCREENING: Glomerular filtration rate (GFR) ≥ 50 ml\u002Fmin (to be performed between day +70 and +100 after HCT unless otherwise stated)\n* PRE-SCREENING: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (to be performed between day +70 and +100 after HCT unless otherwise stated)\n\n  * If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* PRE-SCREENING: Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of protocol therapy\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only)\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH MODERATE TO HIGH-RISK cGVHD (TREATMENT ARM): Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH MODERATE TO HIGH-RISK cGVHD (TREATMENT ARM): Elevated serum\u002Fplasma levels of ST2, CXCL9, MMP-3, and OPN as indicated by moderate or severe risk of chronic GVHD in the test results\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH MODERATE TO HIGH-RISK cGVHD (TREATMENT ARM): No use of ruxolitinib or other Jak inhibitors in the past 14 days\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH MODERATE TO HIGH-RISK cGVHD (TREATMENT ARM): Morphologic remission per day +100 bone marrow\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH MODERATE TO HIGH-RISK cGVHD (TREATMENT ARM): Adequate hematopoietic recovery (hemoglobin \\[Hgb\\] ≥ 8 g\u002FdL, platelets \\[PLT\\] ≥ 50K\u002F mm\\^3)\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH MODERATE TO HIGH-RISK cGVHD (TREATMENT ARM): Negative serum or urine pregnancy test (female participants with childbearing potential only)\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH MODERATE TO HIGH-RISK cGVHD (TREATMENT ARM): Absence of active infection not responding to antibiotics\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH MODERATE TO HIGH-RISK cGVHD (TREATMENT ARM): Absence of progressive acute GVHD. Note: prednisone administration (flat dose of \\\u003C 0.25 mg\u002Fkg) is allowed. Patients receiving any other medication to control active\u002Fprogressive GVHD will be excluded\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH MODERATE TO HIGH-RISK cGVHD (TREATMENT ARM): Absence of any clinically significant uncontrolled sickness\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH LOW-RISK cGVHD (CONTROL ARM): Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH LOW-RISK cGVHD (CONTROL ARM): Low serum\u002Fplasma levels of ST2, CXCL9, MMP-3, and OPN as indicated by low risk of chronic GVHD in the test results\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH LOW-RISK cGVHD (CONTROL ARM): No use of ruxolitinib or other Jak inhibitors in the past 14 days\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH LOW-RISK cGVHD (CONTROL ARM): Morphologic remission per day +100 bone marrow\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH LOW-RISK cGVHD (CONTROL ARM): Adequate hematopoietic recovery (Hgb ≥ 8 g\u002FdL, PLT ≥ 50K\u002F mm\\^3)\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH LOW-RISK cGVHD (CONTROL ARM): Negative serum or urine pregnancy test (female participants with childbearing potential only)\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH LOW-RISK cGVHD (CONTROL ARM): Absence of active infection not responding to antibiotics\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH LOW-RISK cGVHD (CONTROL ARM): Absence of progressive acute GVHD. Note: prednisone administration (flat dose of \\\u003C 0.25 mg\u002Fkg) is allowed. Patients receiving any other medication to control active\u002Fprogressive GVHD will be excluded\n* AFTER DAY +100 TEST RESULTS PATIENTS WITH LOW-RISK cGVHD (CONTROL ARM): Absence of any clinically significant uncontrolled sickness\n\nExclusion Criteria:\n\n* PRE-SCREENING: Prior chemotherapy \\\u003C 14 days prior to study biospecimen collection on day +100 post-HCT\n* PRE-SCREENING: Previous use of ruxolitinib or other JAK-inhibitors is allowed but administration should be stopped for at least 14 days prior to enrollment. Note: Previous use of Jak inhibitors before enrollment (including the pre-HCT period) should be recorded\n* PRE-SCREENING: History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\n* PRE-SCREENING: Active\u002Fprogressive acute GVHD at the time of screening. Prednisone administration (flat dose of \\\u003C 0.25 mg\u002Fkg) is allowed. Patients receiving any other medication to control active\u002Fprogressive GVHD will be excluded\n* PRE-SCREENING: Patients with history of major adverse cardiovascular event (MACE)\u002Fother thrombosis (myocardial infarction \\[MI\\]\u002Fstroke and pulmonary embolism \\[PE\\]\u002Fdeep vein thrombosis \\[DVT\\]) in the past 6 months\n* PRE-SCREENING: Patients with a history of tuberculosis\n* PRE-SCREENING: Clinically significant uncontrolled illness\n* PRE-SCREENING: Active infection not responding to antibiotics\n* PRE-SCREENING: Other active malignancy. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* PRE-SCREENING: Females only: Pregnant or breastfeeding\n* PRE-SCREENING: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* PRE-SCREENING: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)","ALL","18 Years",{"count":20,"type":21},42,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This phase I trial studies how well biomarker-guided ruxolitinib works for the prevention of chronic graft versus host disease (GVHD) in patients that have undergone allogeneic hematopoietic cell transplant (HCT). Allogeneic HCT is the most effective therapy for patients with high-risk blood and bone marrow malignancies. GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. In chronic GVHD (cGVHD), symptoms occur more than three months after transplantation. Despite significant advances in how allogeneic HCTs are conducted, cGHVD remains a major limitation to the long-term success of the transplant and can impact patients' quality of life post-transplant. Checking GVHD biomarkers in patients' blood after allogeneic HCT may help doctors predict how likely the patient is to develop cGVHD. This information can be used to help guide patients with high levels to receive cGVHD preventative therapy with ruxolitinib. Ruxolitinib works by blocking some of the enzymes that are needed for the development of cGVHD, which may be an effective way to prevent cGVHD in patients with high levels of GVHD biomarkers.",[27],"Hematopoietic and Lymphatic System Neoplasm","RECRUITING","2026-07-10",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2026-04-29",{"date":36,"type":21},"2028-06-22",{"name":38,"class":39},"City of Hope Medical Center","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":40},"100053317","transcranial-direct-current-stimulation-for-the-treatment-of-chemotherapy-induced-peripheral-neuropathy-in-cancer-survivors-100053317","NCT07673614","Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors","Improving Sensorimotor Function in CIPN: A Randomized, Sham Controlled, Double Blinded, Crossover Mechanistic Trial of Transcranial Direct Current to the Sensorimotor Cortex","Inclusion Criteria:\n\n* 18 to 85 years of age\n* Diagnosis of cancer, stages I-IV\n* Cancer survivor (not currently receiving chemotherapy, radiation, or immunotherapy)\n* Presence of CIPN defined as new, length-dependent numbness, tingling, and\u002For pain that developed with neurotoxic chemotherapy\n* CIPN20 score ≥ 20\n* Able to walk unassisted\n* Proficient in English\n\nExclusion Criteria:\n\n* Known brain metastases\n* Known neurological conditions aside from chemotherapy-induced peripheral neuropathy (CIPN)\n* History of brain or spinal surgery\n* Neuropathy other than CIPN\n* Significant hearing or vision deficits\n* Vestibulopathy\n* Currently receiving chemotherapy, radiation therapy, or immunotherapy\n* Contraindications to transcranial direct current stimulation (tDCS), including recent seizures\n* Presence of metallic objects in the head\n* Presence of specific implanted medical devices (e.g., deep brain stimulator, cochlear implant, vagus nerve stimulator, spinal cord stimulator, pacemakers, and intracardiac devices)\n* Active scalp dermatological conditions","85 Years",{"count":50,"type":21},50,[52],"NA","This clinical trial tests how well a type of non-invasive brain stimulation called transcranial direct current stimulation (tDCS) works to treat chemotherapy induced peripheral neuropathy (CIPN) in cancer survivors. CIPN is numbness, tingling, pain, and movement problems that can develop after chemotherapy as a result of changes to the nerves. A non-invasive form of brain stimulation called tDCS, applied to the area of the brain involved in sensation and movement, can temporarily improve the ability to detect vibration and temperature, as well as balance and walking, which may improve sensation and reduce pain in cancer survivors with CIPN.",[55,27,56],"Chemotherapy-Induced Peripheral Neuropathy","Malignant Solid Neoplasm","NOT_YET_RECRUITING","2026-07-09",{"date":31,"type":32},{"date":61,"type":21},"2026-08-01",{"date":63,"type":21},"2028-02",{"name":65,"class":39},"University of Michigan Rogel Cancer Center",{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":17,"minAge":18,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},"100594521","phase-1-a-vaccine-cmv-mva-triplex-vaccine-for-the-enhancement-of-cmv-specific-immunity-and-the-prevention-of-cmv-viremia-in-patients-undergoing-haploidentical-hematopoietic-stem-cell-transplant-100594521","NCT07020533","A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant","A Phase 1b Trial of CMV-MVA Triplex Vaccine in Haploidentical Stem Cell Donors and Recipients to Enhance CMV-Specific Immunity and Prevent CMV Viremia in Recipients of Hematopoietic Stem Cell Transplant","Inclusion Criteria:\n\n* DONORS: Documented informed consent of the participant. This can be done in person or informed consent can be obtained remotely.\n\n  * Remote consent, when appropriate, will be obtained per institutional guidelines.\n  * Assent, when appropriate, will be obtained per institutional guidelines.\n  * Adult subjects who require a legally authorized representative (LAR) will not be permitted to be enrolled under this protocol.\n* DONORS: Age: 18 - 75.\n* DONORS: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* DONORS: Agreement by females and males of childbearing potential\\* to use an effective method of birth control (hormonal or barrier method) or abstain from heterosexual activity prior to study entry and for up to 90 days post-vaccination.\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only).\n* RECIPIENTS: Documented informed consent of the participant and\u002For legally authorized representative. This can be done in person or informed consent can be obtained remotely.\n\n  * Remote consent, when appropriate, will be obtained per institutional guidelines.\n  * Assent, when appropriate, will be obtained per institutional guidelines.\n  * Adult subjects who require a legally authorized representative (LAR) will not be permitted to be enrolled under this protocol.\n* RECIPIENTS: Participant must be willing to comply with study and\u002For follow-up procedures, including willingness to be followed for one year post-HCT.\n* RECIPIENTS: Age: 18 - 75.\n* RECIPIENTS: Planned peripheral blood stem cell (PBSC) or bone marrow (BM) HCT for the treatment of the following hematologic malignancies:\n\n  * Lymphoma (Hodgkin and Non-Hodgkin).\n  * Myelodysplastic syndrome.\n  * Acute lymphoblastic leukemia in first or second remission (for acute lymphoblastic leukemia\u002Flymphoblastic lymphoma, the disease status must be in hematologic remission by bone marrow and peripheral blood. Persistent lymphadenopathy on computed tomography (CT) or CT\u002Fpositron emission tomography(PET) scan without progression is allowed.)\n  * Acute myeloid leukemia in first or second remission.\n  * Chronic myelogenous leukemia in first chronic or accelerated phase, or in second chronic phase.\n  * Other hematologic malignancies judged appropriate by the clinical principal investigators (PIs), including chronic lymphocytic leukemia, myeloproliferative disorders and myelofibrosis. Patients with multiple myeloma and those with non-malignant disease such as aplastic anemia are excluded\\*\\*.\n\n    * Adult cases of multiple myeloma (MM) are excluded as HCT is not standard of care for MM and is only performed in very advanced cases with an associated high risk of relapse and non-relapse mortality (NRM). Adults with aplastic anemia are excluded because their standard management includes T cell depletion with agents such as antithymocyte globulin (ATG), which is not permissible on this protocol. Patients undergoing a second haploHCT are not eligible (patients who have undergone a previous autologous HCT are eligible).\n* RECIPIENTS: Patients receiving myeloablative (MA) or reduced intensity conditioning (RIC) are allowed.\n* RECIPIENTS: CMV seropositive.\n* RECIPIENTS: Eligible haploidentical donors will have 2-4 mismatches if human leukocyte antigen (HLA)-A, -B, -C, and -DRB1 typing is used; 2-5 mismatches if HLA-A, -B, -C, -DRB1, and -DQB1 typing is used; and 2-6 mismatches if HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 typing is used. A unidirectional mismatch in either the graft versus host or host versus graft direction is considered a mismatch. The donor and recipient must demonstrate that they are a full haplotype match by being identical at a minimum of one allele (at high resolution deoxyribonucleic acid \\[DNA\\]-based typing) at the following genetic loci: HLA-A, -B, -C, and DRB1 if 8 allele typing is used; HLA-A, -B, -C, -DRB1, and -DQB1 if 10 allele typing is used; and HLA-A, -B, -C, -DRB1-, DQB1, and -DPB1 is 12 allele typing is used.\n* RECIPIENTS: Planned HCT with minimal to no-T cell depletion of graft.\n* RECIPIENTS: Conditioning and immunosuppressive regimens according to institutional guidelines are permitted.\n* RECIPIENTS: Total bilirubin ≤ 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease) (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Aspartate aminotransferase (AST) =\\\u003C 2.5 x ULN (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Alanine aminotransferase (ALT) =\\\u003C 2.5 x ULN (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Estimated creatinine clearance acceptable per institutional guidelines (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Left ventricular ejection fraction (LVEF) ≥ 50%.\n\n  * Note: To be performed within 45 days prior to day 1 of protocol therapy.\n* RECIPIENTS: If able to perform pulmonary function tests: forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and carbon monoxide diffusing capability (DLCO) (diffusion capacity) ≥ 50% of predicted (corrected for hemoglobin).\n\n  * If unable to perform pulmonary function tests: Oxygen (O2) saturation \\> 92% on room air.\n  * Note to be performed within 45 days prior to day 1 of protocol therapy.\n* RECIPIENTS: Seronegative for HIV antigen (Ag)\u002Fantibody (Ab) combination (combo), hepatitis c virus (HCV)\\*, active hepatitis b virus (HBV) (surface antigen negative) and syphilis (RPR) within 2 months of registration and no history of disseminated cutaneous human papillomavirus (HPV) related disease.\n\n  * If seropositive for HIV, HCV or HBV, nucleic acid quantitation must be performed. Viral load must be undetectable.\n* RECIPIENTS: Meets other institutional and federal requirements for infectious disease titer requirements.\n\n  * Note Infectious disease testing to be performed within 45 days prior to day 1 of protocol therapy.\n* RECIPIENTS: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (to be performed within 45 days prior to day 1 of protocol therapy).\n* RECIPIENTS: Agreement by females and males of childbearing potential\\* to use an effective method of birth control (hormonal or barrier method) or abstain from heterosexual activity prior to study entry and up to 90 days post-HCT.\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only).\n\nExclusion Criteria:\n\n* DONORS: Any prior transplant to day 1 of protocol therapy (day 1 defined as the day after donors receive the Triplex vaccine).\n* DONORS: Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 days prior to day 1 of protocol therapy.\n* DONORS: Receipt of any vaccine (licensed or investigational) within 30 days prior to and after the study vaccine.\n* DONORS: Unfit to undergo standard stem cell mobilization and apheresis e.g. abnormal blood counts, history of stroke, uncontrolled hypertension.\n* DONORS: Sickling hemoglobinopathy including hemoglobin (Hb)SS, HbAS, HbSC.\n* DONORS: Donors with impaired cardiac function are excluded. Electrocardiography is routine for potential HCT donors over 60 years old and those with a history of heart disease. Subjects in whom cardiac function is abnormal (excluding 1st degree branch block, sinus bradycardia, sinus tachycardia or non-specific T wave changes) are ineligible for Triplex vaccination.\n* DONORS: Severe psychiatric illness. Mental deficiency sufficiently severe as to make compliance with the donation procedure unlikely and making informed consent impossible.\n* DONORS: Females only: Pregnant or breastfeeding.\n* DONORS: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.\n* DONORS: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics).\n* RECIPIENTS: Any prior investigational CMV vaccine.\n* RECIPIENTS: Experimental anti-CMV chemotherapy in the last 6 months.\n* RECIPIENTS: Live attenuated vaccines (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Medically indicated subunit (Engerix-B for HBV; Gardasil for HPV) or killed vaccines (e.g. influenza, pneumococcal, or allergy treatment with antigen injections) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Allergy treatment with antigen injections (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Alemtuzumab or any equivalent in vivo T-cell depleting agent (or CD34+ selection) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Antiviral medications with known therapeutic effects on CMV such as ganciclovir (GCV)\u002Fvalganciclovir (VAL), foscarnet (FOS), cidofovir, CMX-001, maribavir. Acyclovir has no known therapeutic efficacy against CMV and is allowable as standard of care to prevent herpes simplex virus (HSV) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment EXCEPT letermovir prophylaxis (prior to day 100) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Disease-based radiation therapy (not total body irradiation) (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Other investigational product(s) - concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Other medications that might interfere with the evaluation of the investigational product (planned medications from the time of HCT to day 70 post-HCT).\n* RECIPIENTS: Patients with active autoimmune conditions requiring systemic immunosuppressive therapy within the previous 5 years.\n* RECIPIENTS: Patients considered by PI\u002Fconsenting physicians to have a complicated prior therapy or HCT regimen, or who have a low survival probability (e.g., refractory leukemia and\u002For undergoing 2nd HCT).\n* RECIPIENTS: Poor risk disease\u002Fdisease status including: Chronic myelogenous leukemia (CML) in blast crisis, acute myeloid leukemia (AML)\u002Facute lymphoblastic leukemia (ALL) beyond 2nd remission, multiple myeloma, and aplastic anemia.\n* RECIPIENTS: Females only: Pregnant or breastfeeding.\n* RECIPIENTS: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.\n* RECIPIENTS: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics).",true,"75 Years",{"count":76,"type":21},46,[24],"This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cell transplantation (haploHCT) has advanced to become the predominant procedure for patients lacking a matched donor. Compared to matched related donor transplants, the rate of significant CMV infection is higher in patients undergoing a haploHCT. Significant CMV infection is associated with an increased risk of complications and death. Vaccination is the main preventative approach to limit complications and death in immunocompromised patients at high risk of post-stem cell transplant infections. CMV-MVA Triplex vaccine, is a CMV vaccine based on the attenuated poxvirus, modified vaccinia Ankara (MVA), developed to enhance CMV-specific immunity in both healthy stem cell transplant donors and stem cell transplant patients to prevent significant CMV infection post-stem cell transplant. Giving CMV-MVA triplex vaccine may be safe, tolerable and\u002For effective in enhancing cytomegalovirus (CMV)-specific immunity and preventing CMV viremia in patients undergoing a haploHCT.",[80,81,82,83,84,27,85,86,87,88,89,90],"Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Chronic Lymphocytic Leukemia","Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","Hodgkin Lymphoma","Lymphoblastic Lymphoma","Myelodysplastic Syndrome","Myelofibrosis","Myeloproliferative Neoplasm","Non-Hodgkin Lymphoma","2026-06-30",{"date":93,"type":32},"2026-07-02",{"date":91,"type":32},{"date":96,"type":21},"2028-05-30",{"name":38,"class":39},3,{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":40},"100577469","virtual-reality-for-symptom-management-in-patients-undergoing-hematopoietic-stem-cell-transplantation-100577469","NCT06798701","Virtual Reality for Symptom Management in Patients Undergoing Hematopoietic Stem Cell Transplantation","Symptom Management in the Bone Marrow Transplant Patient Population Using Virtual Reality","Inclusion Criteria:\n\n* Adult patients (≥ 18 years old) admitted to Roswell Park on 5 North for planned hematopoietic stem cell transplantation (HSCT)\n* Must be alert and oriented (Glascow Coma Scale of 15, Nursing Universal Flowsheet) and able to consent to participate in the study\n* Expected to be admitted to Roswell Park inpatient unit for ≥ 1 week\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Pregnant patients\n* Incarcerated patients\n* Patients who are unwilling or unable to follow protocol requirements\n* Individuals that are prone to motion sickness, nausea, dizziness, history of seizure, potential for seizure, history of delirium, at risk for confusion, etc\n* Participants with audio and\u002For visual impairments that would preclude them from using a VR device",{"count":107,"type":21},28,[52],"This clinical trial compares the use of virtual reality to standard care for improving symptom management in patients undergoing hematopoietic stem cell transplantation (HSCT). Significant symptoms experienced by hospitalized HSCT patients include, but are not limited to, depression, tiredness, anxiety, drowsiness, lack of appetite, pain, and overall decreased quality of life and well-being. Virtual reality (VR) as an intervention can provide these patients with a much-needed escape from their reality and has proven results in clinical settings as a distraction therapy. VR technology targets the patient's auditory, visual, and physical contact\u002Ftouch senses, and has been evidenced to improve depression, fatigue, anxiety, appetite, and pain. Virtual reality may improve symptom management in patients undergoing HSCT.",[27,56],"2026-06-29",{"date":91,"type":32},{"date":114,"type":32},"2025-03-14",{"date":116,"type":21},"2026-08-14",{"name":118,"class":39},"Roswell Park Cancer Institute",{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},"100554537","comparing-the-impact-of-four-types-of-meditation-practices-for-relaxation-in-cancer-survivors-100554537","NCT06500377","Comparing the Impact of Four Types of Meditation Practices for Relaxation in Cancer Survivors","A Pilot Study Exploring Four Types of Meditation Practices for Relaxation Among Cancer Survivors","Inclusion Criteria:\n\n* Documented written informed consent of the participant\n* Age: ≥ 18 years\n* Ability to understand and fluently speak English or Spanish\n* No previous training in mind-body relaxation techniques including meditation, yoga, tai chi, qigong, guided imagery, mindfulness-based stress reduction, hypnosis, or cognitive behavior therapy, that exceeds 3 hours. Additionally, no regular practice of mind-body relaxation techniques, or formal experience with mind-body relaxation techniques within the past 12 months\n* Visual Analog Scale (VAS) anxiety score of \\> 3 from a range from 0 to 10. A \"0\" means the lowest anxiety score and a \"10\" means the highest anxiety score\n* Long-term cancer survivors who received surgery to treat their cancer ( \\> 6 months since last treatment) with no history of chemotherapy, radiation therapy, or other systemic therapy (e.g., hormonal therapy) and\u002For have completely recovered from surgery OR patients identified as having pre-cancerous lesions that have been surgically treated (e.g., colon polyp that has been removed)\n* Willingness to:\n\n  * Provide salivary alpha-amylase sample\n  * Complete stress tests and study questionnaires\n  * Be monitored with a Bispectral Index (BIS) device\n\nExclusion Criteria:\n\n* Inability to complete study required time and procedures as outlined in the study procedures section of the protocol\n* Must not have had previous serious illnesses that affect neurological functioning such as strokes, heart attacks, Parkinson disease, etc\n* Ongoing active psychiatric condition, depressive\u002Fbi-polar related disorders, anxiety, psychosis disorders, or substance use that may interfere with the study including panic disorder, major depression, schizophrenia, and bipolar disease\n* Active cancer\n* Cancer survivors who have received chemotherapy, radiation therapy, or any other systemic treatment (e.g., hormonal therapy)\n* Women who are pregnant",{"count":127,"type":21},44,[52],"This clinical trial compares the impact of four types of meditation practices, breathing only, focused attention only, mindfulness only, and breathing, focused attention and mindfulness combined, for relaxation in cancer survivors. Studies show that many patients with cancer experience stress and anxiety. Meditation therapy uses a variety of techniques, such as breathing, sound, or movement, that may help to decrease distress and anxiety and enhance the health and quality of life of patients with cancer. The trial is being done to find out how meditation can help cancer survivors feel relaxed and attain a peaceful state of mind.",[27,56],{"date":132,"type":32},"2026-07-01",{"date":134,"type":32},"2024-06-17",{"date":136,"type":21},"2027-03-12",{"name":38,"class":39},2,{"id":140,"slug":4,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":53,"conditions":143,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":147,"leadSponsor":148,"locationsCount":40},"100644683",{"count":50,"type":21},[52],[55,27,56],"2026-06-24",{"date":111,"type":32},{"date":61,"type":21},{"date":63,"type":21},{"name":65,"class":39},{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":40},"100584908","phase-2-intrathecal-cytarabine-methotrexate-and-hydrocortisone-for-the-prevention-of-high-grade-chimeric-antigen-receptor-t-cell-associated-neurotoxicity-syndrome-100584908","NCT06895473","Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome","A Phase 2 Study of Prophylactic IT Chemotherapy to Prevent High-Grade Chimeric Antigen Receptor (CAR) T-Cell-Associated Neurotoxicity Syndrome","Inclusion Criteria:\n\n* Written informed consent. Participant or legally authorized representative (LAR) must provide written informed consent prior to any study-specific procedures or interventions\n* Age ≥ 18 years. All genders, races, and ethnic groups will be included\n* Must be receiving SOC Yescarta® or Tecartus® in the inpatient setting\n* Agree to adhere to institutional guidelines for contraception during the first 30 days post CAR-T\n\n  * Rationale for eligibility criteria based on contraception and pregnancy (both participants and partners of a sperm-producing participant): It shall be known to all participants that the effects of CAR-T or IT chemotherapy on the developing human fetus are unknown. For this reason, persons of reproductive potential must agree to use adequate contraception. Should a participant or participant's sexual partner become pregnant or suspect a pregnancy while participating in this study, the individual should inform their treating physician immediately\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Platelet count \\> 50,000\u002Fmm\\^3 (μL)\n* Adequate coagulation tests including international normalized ratio (INR) \\\u003C 1.6 and fibrinogen \\> 100\n\nExclusion Criteria:\n\n* Active\u002Fconcurrent diagnosis of any central nervous system (CNS) hematologic malignancy\n\n  * History or presence of CNS disorder such as poorly controlled seizure disorder (seizure within the 12 months), transverse myelitis, cerebrovascular ischemia\u002Fhemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement\n* Known history of hypersensitivity to IT chemotherapy\n* Subject has a contraindication to LP including:\n\n  * Presence of a posterior fossa mass\n  * Skin infection near puncture site\n  * Uncorrected bleeding diathesis\n  * Suspicion of increased intracranial pressure\n  * Acute spinal cord trauma\n* Subject is receiving an antiplatelet and\u002For anticoagulant that cannot be held prior to LP according to best available evidence\n* Known bleeding disorders\n* Any other significant medical illness, abnormality, or condition that would, in the Investigator's judgement, make the participant inappropriate for study participation or would put the participant at risk",{"count":157,"type":21},26,[159],"PHASE2","This phase II trial tests how well cytarabine (Ara-C), methotrexate, and hydrocortisone given between the spinal cord and the membranes that protect it (intrathecal \\[IT\\]) works in preventing high-grade immune effector-associated neurotoxicity syndrome (ICANS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy. ICANS is a challenging complication of CAR T-cell therapy that causes neurological effects varying from mild headaches or temporary confusion to hallucinations, swelling in the brain, and seizures. Between 20%-70% of patients receiving CAR T-cell therapy show symptoms of neurotoxicity.",[27],{"date":163,"type":32},"2026-06-26",{"date":165,"type":32},"2025-06-04",{"date":167,"type":21},"2027-12-31",{"name":169,"class":39},"OHSU Knight Cancer Institute",{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":40},"100621006","a-virtually-delivered-diet-intervention-laso-3-for-the-improvement-of-chemotherapy-induced-peripheral-neuropathy-in-cancer-survivors-post-treatment-100621006","NCT07365007","A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors Post-treatment","Feasibility of a Virtually Delivered LASO-3 Diet Intervention for Chemotherapy-Induced Peripheral Neuropathy in Post-Treatment Cancer Survivors","Inclusion Criteria:\n\n* 18 years or older\n* At least three months since last receiving neurotoxic chemotherapy\n* Self-report moderate (≥ 2\u002F4) numbness and tingling on the Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE™) Numbness and Tingling Severity Item in the last week\n* Speak\u002Fread English\n* Have access to the internet\n\nExclusion Criteria:\n\n* Pre-existing peripheral neuropathy from any cause\n* Plan to begin a new prescription of duloxetine (i.e., first-line treatment for CIPN pain) during the study period\n* Are enrolled in symptom management trials that may alter CIPN severity\n* High grade inflammatory disease such as lupus, Crohn's disease, or rheumatoid arthritis\n* Routine nonsteroidal anti-inflammatory drug (NSAID) or steroid supplementation\n* Consuming an average three or more servings of fish per week and\u002For consuming fish oil capsules containing eicosapentaenoic acid (EPA)+ docosahexaenoic acid (DHA) daily or consuming flax oil capsules daily\n* Consuming an average of less than 5 servings of sweets, candy bars, chocolate, doughnuts, cookies, cakes, pie, brownies, ice cream, pastries, or sugar sweetened beverages (e.g., soda or coffee\u002Ftea) per week",{"count":50,"type":21},[52],"This clinical trial studies whether a virtually delivered diet intervention focused on lower added sugar, higher fiber, and higher omega 3 fatty acid (LASO-3) can be used to improve chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors after treatment. Cancer survivors often experience CIPN during and after cancer treatment with neurotoxic chemotherapy. CIPN is characterized by nerve damage from chemotherapy that leads to numbness, tingling, or pain in the hands or feet. However, there are few treatments to manage CIPN. Inflammation contributes to the development of CIPN and dietary patterns that have been demonstrated to improve diet quality and reduce inflammation in cancer survivors may be promising for use as a CIPN management strategy. The LASO-3 diet intervention consists of virtually delivered nutrition education sessions provided by a Registered Dietitian. The sessions focus on three dietary goals, informed by the United States Dietary Guidelines for Americans: 1) lowering added sugar intake to \\\u003C 10% of daily calories, 2) increasing daily fiber intake to ≥ 20 grams, and 3) increasing intake of moderate-high omega-3 seafood to three or more servings weekly or 3300-3400 mg\u002Fday of alpha-linolenic acid (e.g., plant-based sources include canola or flaxseed oil, walnuts, or flaxseed or chia seeds). The Registered Dietitian tailors the sessions to the patient based on information and feedback obtained throughout the sessions. The LASO-3 diet intervention may be an effective way to improve CIPN in cancer survivors after treatment.",[55,27,56],"2026-06-22",{"date":183,"type":32},"2026-06-25",{"date":185,"type":32},"2026-02-23",{"date":187,"type":21},"2028-03-01",{"name":65,"class":39},{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":73,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":209},"100537529","comparing-telephone-symptom-monitoring-interventions-for-managing-symptoms-and-psychological-distress-during-oral-anti-cancer-treatment-100537529","NCT06279013","Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment","Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment","SYMON","Inclusion Criteria:\n\n* PRACTICES: All institutions participating in the practice are National Cancer Institute Community Oncology Research Program (NCORP) affiliates or sub-affiliates.\n* PRACTICES: Administer oral therapy to at least 40 patients per year that meet protocol eligibility criteria.\n* PRACTICES: Completion and submission of the NRG-CC012CD Letter of Intent (LOI) (posted on the Cancer Trials Support Unit \\[CTSU\\] website).\n* PRACTICES: Having a social worker licensed in behavioral counseling or other person eligible for behavioral licensing in the practice's state or territory (if licensure is required by state or territory) who can be trained to deliver TIPC or willingness of practice to work with TIPC intervener contracted by the study team. Note: If the practice's social worker or other behavioral health professional is trained to deliver TIPC, they will be compensated for their time training and delivering the TIPC intervention.\n* PRACTICE PERSONNEL: Age ≥ 18 years.\n* PRACTICE PERSONNEL: Planned to be involved in usual care for at least one enrolled patient during patient's participation in the study.\n* PRACTICE PERSONNEL: For a social worker or other behavioral health professional who will deliver TIPC intervention, licensure, or eligibility for licensure in behavioral counseling if required by the state or territory.\n* PRACTICE PERSONNEL: The practice personnel must provide study-specific informed consent prior to study entry.\n* RETAIN PRACTICE PARTICIPATION: In order to maintain participation in the study, practices must enroll at least 8 patients in the first 6 months (based upon the practice's monthly tracking reports) the practice is open to patient accrual to ensure that the practice can meet the accrual goals. If a practice does not meet this criterion they will be replaced.\n* RETAIN PRACTICE PARTICIPATION: Complete monthly forms on actions taken on IVR symptom reports. If fewer than 2 forms are completed in the first 6 months of practice's participation, practice will be replaced.\n* RETAIN PRACTICE PARTICIPATION: Participate in monthly study calls for the duration of practice's participation in the study.\n* PATIENTS: Starting a new course of an oral anti-cancer agent (the list of agents is posted to the CTSU website) other than sex hormone inhibitors, within 4 weeks after registration or have started an oral anti-cancer agent in the past 8 weeks.\n* PATIENTS: All concomitant medications and supportive care treatments are acceptable.\n* PATIENTS: Age ≥ 18 years.\n* PATIENTS: Able to speak and understand English or Spanish.\n* PATIENTS: Access to a telephone and ability to answer questions via telephone in English or Spanish.\n* PATIENTS: The patient must provide study-specific informed consent prior to study entry and authorization permitting release of personal health information.\n\nExclusion Criteria:\n\n* PRACTICES: Active telephone symptom management program at the practice that is beyond symptom and oral agent adherence monitoring.\n* PATIENTS: Only receiving treatment with sex hormone inhibitors.\n* PATIENTS: Enrollment in the intervention arm of another symptom management trial at intake into the trial. Participation in lifestyle trials with primary outcomes other than symptoms is acceptable.\n* PATIENTS: Currently receiving regular behavioral counseling for psychological symptoms. Regular behavioral counseling is defined as at least two counseling sessions with a behavioral health care provider scheduled within the past two months. Patients who completed behavioral counseling within 2 months prior to registration are eligible. Behavioral counseling for issues other than psychological symptoms (e.g., as part of weight loss or smoking cessation program) is not an exclusion criterion.\n* PATIENTS: Pregnancy at intake into the trial.",{"count":198,"type":21},600,[52],"In this clinical trial, symptom monitoring (interactive voice response \\[IVR\\] is compared to automated telephone symptom management \\[ATSM\\] and telephone interpersonal counseling \\[TIPC\\]) for reducing symptom burden and psychological distress (depressive and anxiety symptoms) among people receiving oral anti-cancer treatment. Symptoms are the number one driver of treatment interruptions and unscheduled health services use. To reduce the risk of these events, symptom monitoring and management are necessary. However, these services are not implemented routinely, especially in the community oncology settings. Further, depressive and anxiety symptoms are a key barrier to enacting symptom self-management strategies. IVR is a form of symptom monitoring where patients, when called, enter their symptom ratings over the phone. Their symptom summary is sent to their provider, and patients may be advised to reach out to their oncology provider, based on their symptoms. The ATSM intervention combines IVR assessments with a Symptom Management and Survivorship educational handbook with self-management strategies. Patients receiving ATSM enter their symptom ratings over the phone and have their symptoms reported to their provider, but patients are also directed to the handbook for strategies to manage elevated symptoms. Patients receiving ATSM who report being anxious, discouraged, or sad will also receive TIPC, which targets psychological distress and its connection to social support and interpersonal communication. Information gathered from this study may help researchers learn more about the best ways to manage patient symptoms and improve patient outcomes.",[27,56],{"date":183,"type":32},{"date":204,"type":32},"2024-10-14",{"date":206,"type":21},"2028-05-01",{"name":208,"class":39},"NRG Oncology",34,{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":40},"100634078","dental-cleaning-to-prevent-chronic-graft-versus-host-disease-100634078","NCT07535008","Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* T-replete allogeneic hematopoietic cell transplantation for any indication. History of prior transplantation is allowed. Any conditioning regimen is allowed\n* One of the following HCT donor types:\n\n  * 9\u002F10 or 10\u002F10 human leukocyte antigen (HLA)-matched unrelated donor\n  * Cord blood\n* Willing to have an in-person 1-year long-term follow-up (LTFU) visit including an oral medicine at Fred Hutch (FH)\n* Ability to understand and sign a written informed consent document (or legal representative)\n\nExclusion Criteria:\n\n* Edentulous state\n* Bone marrow as graft source\n* Use of post-transplantation cyclophosphamide (PTCy) or ruxolitinib as GVHD prophylaxis\n* Use of anti-thymocyte globulin (ATG) in conditioning",{"count":217,"type":21},45,[52],"This clinical trial evaluates the feasibility and effectiveness of a post-transplant dental cleaning for the prevention of chronic graft versus host disease (GVHD) in patients undergoing an allogeneic hematopoietic cell transplant (HCT). HCT is the only curative treatment for some types of blood cancer. Unfortunately, this approach can lead to the development of GVHD, which is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Some research has shown that the bacteria that is present in the dental plaque soon after transplant may affect the development of chronic GVHD. Dental cleanings prior to transplant are part of the normal standard of care for patients undergoing HCT. Adding an additional cleaning shortly after HCT may be effective for preventing the development of chronic GVHD.",[221,222,27],"Chronic Graft Versus Host Disease","Acute Graft Versus Host Disease","2026-06-18",{"date":181,"type":32},{"date":226,"type":21},"2026-07-15",{"date":228,"type":21},"2029-04-30",{"name":230,"class":39},"Fred Hutchinson Cancer Center",{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":40},"100615315","a-mindfulness-based-stress-reduction-program-for-improving-mental-health-outcomes-for-underserved-cancer-patients-in-minnesota-100615315","NCT07291011","A Mindfulness-Based Stress Reduction Program for Improving Mental Health Outcomes for Underserved Cancer Patients in Minnesota","A Pilot Study of Mindfulness-Based Stress Reduction (MBSR) in Patients With Cancer Experiencing Stress Who Live in Underserved and Rural Regions of Minnesota","Inclusion Criteria:\n\n* Patients with a history of cancer, or currently have cancer\n* Patients reporting \\> 4\u002F10 emotional distress on a 0-10 scale within the past six months\n* Patients with a Rural-Urban Commuting Area (RUCA) code of 4 or greater\n* Have a computer or smartphone\n* Willing to complete questionnaires\n\nExclusion Criteria:\n\n* Non-English-speaking patients\n* Life expectancy \\\u003C 12 months\n* Active psychiatric disease",{"count":217,"type":21},[52],"This clinical trial evaluates whether a virtual stress reduction program that uses mindfulness-based stress reduction (MBSR) techniques works to improve mental health outcomes in cancer patients living in underserved\u002Frural regions of Minnesota. 80% of Minnesota counties are considered mental health care shortage areas. This shortage disproportionately impacts Minnesotans living in underserved and rural regions as they have to travel further for mental health care services. Interventions that provide patients with mental health resources from the comfort of their own home help to reduce barriers that limit access to mental health care. MBSR courses can help patients control their responses to stressful events, reduce the impact of chronic stress, develop more effective ways to cope with medical\u002Fpsychological conditions, and increase overall sense of well-being. MBSR courses may serve as a way to bridge the gap between mental health care and patients with cancer living in underserved\u002Frural regions of Minnesota.",[27,56],{"date":243,"type":32},"2026-06-23",{"date":245,"type":32},"2025-11-05",{"date":247,"type":21},"2029-11-15",{"name":249,"class":39},"Mayo Clinic",{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":74,"enrollmentInfo":257,"targetDuration":4,"studyType":22,"phases":259,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":40},"100579650","phase-2-psilocybin-with-psychotherapy-for-improving-chronic-pain-in-cancer-patients-requiring-opioids-100579650","NCT06827054","Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids","Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids","Inclusion Criteria:\n\n* Age ≥ 18 and ≤ 75 years old\n* Diagnosis of active cancer, any stage\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Estimated prognosis of ≥ 3 months at the time of enrollment, determined by participant's primary oncologist or palliative physician\n* Diagnosis of moderate to severe pain (reported average pain score ≥ 4 on the 11-point Numerical Rating Scale) that is chronic (≥ 3 months) and secondary to cancer or cancer treatment\n* Pain regimen has been escalated to opioid therapy\n\n  * Participants must be on stable pain regimen for at least one month prior, with no intention to adjust pain regimen during the study period\n* Participants must be ≥ 4 weeks beyond treatments\u002Fprocedures that, in the opinion of the study physician, would significantly affect outcomes related to pain and physical function (e.g., surgery or radiation). Participants may otherwise receive cancer-directed treatment throughout the study period\n* Have no known procedures\u002Ftreatments scheduled in advance that would prohibit patient from completing or significantly delaying completion of the study\n\n  * The participant has no vacations or plans to be out of town during their study enrollment\n* Participants must not plan for additional treatments\u002Fprocedures that, in the opinion of the study physician, would significantly affect outcomes related to pain and physical function (e.g., surgery or radiation) for ≥ 4 weeks following psilocybin treatment initiation. Participants may otherwise receive cancer-directed treatment throughout the study period\n* No use of other illicit substances (excluding cannabis) within the past year based on self-report at screening and routine urine toxicology screen\n* Participants must be able to read, write, and speak English\n* Participants must be able to swallow pills\n* Agree to refrain from using any unprescribed psychoactive drugs, including alcoholic beverages, ≤ 24 hours of before each psilocybin administration. Exceptions include:\n\n  * Daily use of caffeine or nicotine\n  * Prescribed benzodiazepine medications and non-benzodiazepine sleeping medications will be allowed to continue through the study period for participants who have been on a stable dose of such a medicine for ≥ 6 weeks prior to screening\n* Participants using cannabis, including legal cannabis, for any purpose must agree to refrain from use beginning at two weeks before dosing and one week following completion of dosing (7-8 weeks total, dependent on frequency of prior use)\n\n  * Participants will not be withdrawn from the trial for a positive cannabis result during the initial screening drug test. However, participants who test positive for cannabis at the second drug test on visit 10 will be withdrawn from the trial\n* Participants must agree to be driven home after each experimental session and not drive or operate heavy machinery ≤ 16 hours of ingesting psilocybin\n* Participants must provide an emergency contact (relative, spouse, close friend, or other support person) willing and able to be reached by the investigators if the participant is unreachable by study staff or in an emergency\n* The participant agrees to take part in all study procedures, including the assessments, psychological evaluations, and dosing day requirements\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Participants who are pregnant or breast-feeding\n* Participants of childbearing potential who decline to use a highly effective dual contraceptive method for the duration of the study\n* Participants with a condition impairing oral intake or digestive absorption\n* Cognitive impairment as defined by Montreal Cognitive Assessment (MOCA) score \\\u003C 23\n* Medical conditions or serious abnormalities of complete blood count, chemistries, or electrocardiography (ECG) that in the opinion of the study physician would preclude safe participation in the trial. Some examples include: congestive heart failure, valvular heart disease, recent acute myocardial infarction or evidence of ischemia, clinically significant arrhythmias (e.g., ventricular fibrillation, torsades) or clinically significant ECG abnormality (e.g. corrected QT interval using Fridericia's Correction Formula \\[QTcF\\] interval \\> 450 in males and \\> 470 in females), uncontrolled hypertension (systolic blood pressure \\[BP\\] ≥ 140 or diastolic BP ≥ 90 on three separate occasions), congenital long QT syndrome, renal dysfunction (i.e. creatinine clearance \\[CrCl\\] \\\u003C 40 mL\u002Fmin), liver cirrhosis or hepatic dysfunction (indicated by gamma-glutamyltransferase \\[GGT\\], aspartate aminotransferase \\[AST\\], or alanine aminotransferase \\[ALT\\] \\> 3 x ULN \\[upper limit of norm\\] or total bilirubin \\[bili\\] \\> 3.0 mg\u002Fdl, or Child Pugh over class C), paraneoplastic syndrome, respiratory failure, dementia, delirium, known cerebral aneurysm, seizure disorder, stroke\u002Ftransient ischemic attack (TIA) in past year, cancer with known central nervous system (CNS) involvement, previously treated brain metastasis, or other major CNS disease\n* Participants who have a personal history of, or a current diagnosis of the following: primary psychotic disorder, major depressive disorder with psychotic features, bipolar affective disorder type 1 or history of or current dissociative identity disorder\n* Participants who have an ongoing substance use disorder (defined as active in the past year)\n* Participants with first-degree relatives with schizophrenia or bipolar disorder may be eligible depending on their age and personal and family psychiatric history. The decision will be made by the principal investigator and study psychiatrist or on-call psychiatric provider based on risk assessment\n* Active suicidal behavior (interrupted or aborted attempt; preparatory acts) as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) connotating either passive or active suicidal intent; OR one of the following:\n\n  * History of suicide attempt(s) within the past year (≤ 365 days)\n  * Have any suicidal ideation or thoughts, in the opinion of the study physician or principal investigator (PI), that presents a serious risk of suicidal or self-injurious behavior\n* Any contraindications to undergoing an fMRI scan, including having metal implants or metal fragments in the body\n* Participants who have hypersensitivity to the ingredients of the IMP (Investigational Medicinal Product) listed below:\n\n  * Indol alkaloids including psilocybin and psilocin\n  * Constituents of Psilocybe cubensis including protein, fats, carbohydrates, ergosterols, beta-glucan, and polyphenols\n  * Hydroxypropyl methylcellulose (HPMC) capsules\n* Participants who are taking medications with significant potential to interact with study medications will be exclusionary if they cannot be tapered. The taper interval will be at least five times the half-life. These medications include the following:\n\n  * Selective serotonin reuptake inhibitors (SSRIs)\n  * Serotonin and norepinephrine reuptake inhibitors (SNRIs)\n  * Tricyclic antidepressants (TCAs)\n  * Efavirenz\n  * Serotonin-acting dietary supplements (i.e., 5-hydroxy-tryptophan or St. John's wort)\n  * Centrally acting serotonergic agents (e.g., monoamine oxidase \\[MAO\\] inhibitors)\n  * Antipsychotics for a psychiatric disorder (e.g., first and second generation)\n\n    * Antipsychotics that are utilized for nausea, insomnia, or other non-psychiatric condition will be permitted, but patients will be asked to refrain from use 8 hours prior to dosing sessions\n  * Mood stabilizers (e.g., lithium, valproic acid)\n  * Aldehyde dehydrogenase inhibitors (e.g., disulfiram)\n  * Significant inhibitors of UGT 1A9 or UGT 1A10\n* Use of serotonergic hallucinogens (e.g., psilocybin, lysergic acid diethylamine \\[LSD\\]) within the past 12 months or significant lifetime use (\\> 25 uses)\n* Those with a history of prior violent and\u002For drug-related felonies\n* Those currently incarcerated will be excluded\n* Unwilling or unable to follow protocol requirements\n* Any social circumstance which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug",{"count":258,"type":21},20,[159],"This phase II trial studies whether psilocybin with psychotherapy is safe and if it works for improving chronic pain in cancer patients who require opioids to manage their pain. Psilocybin is taken from the mushroom Psilocybe mexicana. Psilocybin acts on the brain to cause hallucinations (sights, sounds, smells, tastes, or touches that a person believes to be real but are not real). This may impact a patient's \"total pain\", a view that accounts for the psychological, spiritual, and social factors that contribute to their experience of pain. Psychotherapy uses methods such as discussion, listening, and counseling to help patients change the way they react to environmental triggers that may cause a negative reaction. Giving psilocybin with psychotherapy may be safe and helpful for improving chronic pain in cancer patients who require opioids to manage their pain.",[27,56],{"date":181,"type":32},{"date":264,"type":21},"2026-08-15",{"date":266,"type":21},"2027-05-05",{"name":118,"class":39},{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":276,"phases":4,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":279,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":40},"100565271","using-induced-pluripotent-stem-cells-to-model-cancer-therapy-related-adverse-events-100565271","NCT06640010","Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events","Inclusion Criteria:\n\n* Any patient \\>= 18 years of age\n* Previously treated, planned or currently receiving any potentially toxic cancer therapy including but not limited to chemotherapy, targeted and immunotherapies\n\nExclusion Criteria:\n\n* Inability on the part of the patient to understand the informed consent or be compliant with the protocol",{"count":275,"type":21},30,"OBSERVATIONAL","This study is being done to find out if patient blood samples can be used to perform individualized modeling of cancer therapy-related side effects.",[27,56],{"date":243,"type":32},{"date":281,"type":32},"2025-02-12",{"date":283,"type":21},"2027-12-15",{"name":249,"class":39},{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":73,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":22,"phases":294,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":40},"100609588","virtual-reality-viewing-of-unaltered-streetscape-versus-digitally-manipulated-opposite-streetscape-to-assess-psychosocial-response-in-participants-100609588","NCT07216534","Virtual Reality Viewing of Unaltered Streetscape Versus Digitally Manipulated Opposite Streetscape to Assess Psychosocial Response in Participants","Piloting a Virtual Reality-Based, Randomized Controlled Trial of Psychosocial Responses to Neighborhood Physical Disorder","Inclusion Criteria:\n\n* Adults 18+\n* Must currently live (4+ night\u002Fweek) at the residence being studied. Only one resident per household will be selected\n* Must understand and be able to read English\n* Must agree to have residence photographed\n* Must be able to wear a VR head mounted display\n* Must live in neighborhood that has been selected for study\n* Must be willing and able to attend an approximately 2 hour in-person visit on Ohio State University (OSU) campus\n\nExclusion Criteria:\n\n* Pregnant women\n* Visual or mobility impairment\n* Cannot have epilepsy or other condition that would inhibit them from being able to use a VR headset",{"count":293,"type":21},32,[52],"This clinical trial compares virtual reality viewing of an unaltered streetscape versus a digitally manipulated opposite streetscape to assess the psychosocial response in participants. Visible measures of neighborhood factors might be associated with health outcomes and risk factors of those outcomes. Short-term exposure to virtual reality environments representing very high or very low levels of neighborhood physical disorder - presence or absence of garbage\u002Flitter, presence or absence of graffiti, presence or absence of an abandoned building, presence or absence of large dumpsters, poor or very well-kept building conditions, poor or very well-kept yard conditions, poor or very well-kept road verge conditions may be a safe and effective way to assess psychosocial response in participants.",[27,56,297],"Psychiatric Disorder","2026-06-17",{"date":181,"type":32},{"date":301,"type":21},"2026-09-01",{"date":303,"type":21},"2026-12-31",{"name":305,"class":39},"Ohio State University Comprehensive Cancer Center",{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":22,"phases":314,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":40},"100644173","the-high-fiber-program-to-increase-fiber-intake-among-patients-undergoing-allogeneic-hematopoietic-cell-transplant-100644173","NCT07664670","The High Fiber Program to Increase Fiber Intake Among Patients Undergoing Allogeneic Hematopoietic Cell Transplant","Pilot Study to Evaluate the Feasibility of High Fiber Program in Patients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)","Inclusion Criteria:\n\n* PRE-SCREENING INCLUSION: Documented informed consent of the participant and\u002For legally authorized representative\n* PRE-SCREENING INCLUSION: Age: ≥ 18 years\n* PRE-SCREENING INCLUSION: Within healthy body mass index (BMI) range 18-29 at the time of pre-screening consent\n* PRE-SCREENING INCLUSION: Ability to read and understand English for questionnaires\n* PRE-SCREENING INCLUSION: Patients must be scheduled to receive HCT within the next 30 days after pre-screening consent\n* MAIN INCLUSION: Documented informed consent of the participant and\u002For legally authorized representative\n* MAIN INCLUSION: Age: ≥ 18 years\n\n  * Patients ≥ 75 years of age that are otherwise eligible to undergo allogeneic HCT are included\n* MAIN INCLUSION: Karnofsky performance status ≥ 70%\n* MAIN INCLUSION: Within healthy BMI range 18-29 at the time of consent\n* MAIN INCLUSION: Ability to read and understand English for questionnaires\n* MAIN INCLUSION: Patients receiving myeloablative or reduced intensity conditioning regimens\n* MAIN INCLUSION: Adequate organ function consistent with institutional standards for HCT\n* MAIN INCLUSION: Patients must be scheduled to receive HCT within 3 weeks of consent\n* MAIN INCLUSION: Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (within 45 days prior to the start of conditioning)\n\n  * If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* MAIN INCLUSION: Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months post-HCT\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only)\n\nExclusion Criteria:\n\n* PRE-SCREENING EXCLUSION: Clinically significant uncontrolled illness\n* PRE-SCREENING EXCLUSION: Active infection requiring antibiotics\n* PRE-SCREENING EXCLUSION: History of chronic gastrointestinal conditions such as inflammatory bowel disease or Crohn's disease\n* PRE-SCREENING EXCLUSION: Medical contraindications to incorporating fiber in their diet as determined by the treating physician\n* PRE-SCREENING EXCLUSION: Self-reported major dietary restrictions limiting fiber intake\n* PRE-SCREENING EXCLUSION: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* PRE-SCREENING EXCLUSION: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)\n* MAIN EXCLUSION: Clinically significant uncontrolled illness\n* MAIN EXCLUSION: Active infection requiring antibiotics\n* MAIN EXCLUSION: History of chronic gastrointestinal conditions such as inflammatory bowel disease or Crohn's disease\n* MAIN EXCLUSION: Medical contraindications to incorporating fiber in their diet as determined by the treating physician\n* MAIN EXCLUSION: Self-reported major dietary restrictions limiting fiber intake\n* MAIN EXCLUSION: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* MAIN EXCLUSION: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)",{"count":127,"type":21},[52],"This clinical trial studies whether the High Fiber Program can be used to increase fiber intake in patients undergoing allogeneic hematopoietic cell transplant (HCT). Allogeneic HCT is a procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor. This is often a sister or brother, but could be an unrelated donor. It is a potentially curative therapy for many conditions that affect the blood and blood-forming organs, but many patients must manage post-transplant complications, especially graft versus host disease (GVHD). GVHD occurs when the transplanted cells from a donor attack the body's normal cells causing skin rash or blisters, dry mouth, or dry eyes. The environment and health of the gut is important in allogeneic HCT patients, with an unhealthy gut environment and\u002For health leading to inflammation and possibly GVHD. Research has shown that diets high in fiber may improve the environment and health of the gut as well as outcomes following transplant; however, fiber intake remains low among patients. The High Fiber Program is a dietitian-led counseling program which teaches patients how to introduce high fiber foods into their diet and identify food choices and personalized strategies that will help them change their diet. The High Fiber Program may be an effective way to increase fiber intake in patients undergoing allogeneic HCT.",[27],"2026-06-16",{"date":144,"type":32},{"date":320,"type":21},"2027-02-13",{"date":322,"type":21},"2028-06-03",{"name":38,"class":39},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":22,"phases":332,"briefSummary":333,"conditions":334,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":337,"leadSponsor":338,"locationsCount":40},"100641912","phase-1-cannabis-gummy-for-the-improvement-of-sleep-and-quality-of-life-in-patients-with-cancer-pillow-trial-100641912","NCT07658677","Cannabis Gummy for the Improvement of Sleep and Quality of Life in Patients With Cancer, Pillow Trial","Piloting a Novel Therapeutic for Sleep Disturbance in Palliative Care Over 5 Weeks: The PILLOW Study","Inclusion Criteria:\n\n* New patients in the OSUCCC's Palliative Care clinics who have histologically or cytologically confirmed malignancy of any anatomic site. This applies to either newly diagnosed cancer or those with preexisting malignancy receiving treatment\n* Reported sleep disturbance (≥ 4) in the Edmonton Symptom Assessment System, the clinic's symptom screener administered at every visit\n* Patients with active cancers and are under any line of treatment or have received cancer treatment in the past 6 months (please see notable exceptions in the exclusion criteria - patients taking checkpoint inhibitors and investigational agents will not be eligible)\n* If patients are currently receiving cancer therapy, they must have been taking their current anti-cancer intervention\u002F therapy regimen for at least one month prior to enrollment (to ensure no safety or toxicity issues with study drug initiation)\n* Age ≥ 18 years\n* English speaking with the ability to understand and the willingness to sign a written informed consent document\n* Eastern Cooperative Oncology Group performance status ≤ 3\n* Total bilirubin: \\\u003C 3X institutional upper limit of normal (1.5 mg\u002Fdl) (within the past 3 months or predating their current cancer regimen)\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]): \\\u003C 3X institutional upper limit of normal (within the past 3 months or predating their current cancer regimen)\n\n  * AST: \\\u003C 3X institutional upper limit of normal (10-39 U\u002FL)\n  * ALT: \\\u003C 3X institutional upper limit of normal (10-52 U\u002FL)\n* Glomerular filtration rate (GFR): ≥ 30 mL\u002Fmin\u002F1.73 m\\^2 using Cockcroft-Gault (within the past 3 months or predating their current cancer regimen)\n* Normal electrocardiogram (EKG); or non-normal EKG with no significant arrhythmias or severe congestive heart failure (CHF). A normal EKG defined as sinus rhythm with no ST or T wave changes any clinically concerning EKGs will be reviewed by the study physician to determine participant eligibility into the study (within the past 3 months or predating their current cancer regimen)\n* Patients are allowed to take any type of analgesic pain medication at baseline, but must be on a stable dose of pain medication for two weeks and not requiring rapid dose escalation\n* Individuals able to become pregnant will agree to practice a highly effective form of birth control. Contraception including oral birth control pills, intrauterine device (IUD), condoms, abstinence must be used alone or in combination for the duration of enrollment\n* Agree to study requirements, as described in the consent form:\n\n  * No driving, use of heavy machinery, or caring for children for 12 hours (hrs) after dose\n  * Wearing fitness tracker 24\u002F7 for the duration of the study and are able to charge the device once per week.\n  * No cannabis (i.e., outside of provided study drug), or illegal drug use (e.g., methamphetamine, non-prescription opioids or fentanyl)\n  * Calls so that study staff can monitor dosing\n  * Completing weekly ecological momentary assessment (EMA) questionnaires\n\nExclusion Criteria:\n\n* History of hypersensitivity to cannabis, THC, or CBD\n* Current, regular use of cannabis\u002Fmarijuana, THC-containing prescription medications (dronabinol\u002FMarinol\u002FSyndros, nabilone\u002FCesamet), prescription CBD (Epidiolex), or over-the-counter CBD oil within the past 6 months\n* Concurrent use of medications that are contraindicated with medical cannabis: valproate, clobazam, warfarin, fluoxetine, disulfiram, tamoxifen, Ibrance, Gleevec, amphetamines, buprenorphine, methadone, alprazolam, amiodarone, fluconazole, ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin. The study physician will review eligibility for participants taking medications that are moderate to strong inhibitors and inducers of enzymes CYP3A4 (epidiolex, marinol), CYP2C19 (epidiolex), and CYP2C9 (marinol)\n* The following medications if being used to treat sleep: benzodiazepines or nonbenzodiazepine medications, antidepressants, antihistamines, supplements (e.g., melatonin)\n* Cardiac conditions contraindicated for cannabis use, moderate\u002Fsevere or unstable CHF, symptomatic valvular heart disease, and uncontrolled arrhythmias as reviewed by the study team physician. Investigators will consult with a cardio-oncologist if needed\n* Abnormal screening ECG with corrected QT (QTc) intervals of ≥ 450 (males) and ≥ 460 (females), as reviewed by the study physician\n* Baseline orthostatic hypotension drop of blood pressure (BP) ≥ 20 mmHg, or in diastolic BP of ≥ 10mmHg or experience of lightheadedness or dizziness during the test\n* Based on a measurement at baseline, we will exclude participants with current hypertension defined as BP \\> 165\u002F100, abnormal ECG results or a resting heart rate defined as \\> 110bpm\n* Concomitant use of checkpoint inhibitors (e.g., anti-PD1, PDL1, CTLA4)\n* Current use of investigational agents or \\\u003C 3 months after the use of investigational agents\n* Diagnosis of sleep apnea\n* Allergy to any constituent\u002Fingredient contained in the edible doses\n* Psychiatric illness\u002Fsocial situations that would limit adherence with study requirements (e.g., bipolar disorder, psychosis). Mild\u002Fmoderate mood disorders treated by medications that are not expected to increase cannabis-induced sedation\u002Fimpairment are acceptable with physician approval\n* Any known or suspected history or family history of schizophrenia, bipolar disorder, or other psychotic illness\n* Pregnant or breastfeeding\n* Sole caretaker of minor children living in the household\n* History of seizure disorder, epilepsy (controlled or uncontrolled)\n* Current legal obligations (parole, probation, incarceration)\n* Current substance use disorder (including cannabis use disorder), or currently enrolled in substance use treatment\n* Self-reported cannabis and synthetic cannabinoid use in the past 6 months (medical or non-medical use is exclusionary)\n* Self-reported illicit drug use in past 60 days (ex: methamphetamine, heroin, illicit fentanyl) or self-reported daily alcohol use\n* No access to internet\u002Fdata or devices needed to participate in video calls (day 14) and EMA assessments",{"count":50,"type":21},[24,159],"This clinical trial tests how well a cannabis gummy works in improving sleep and quality of life in patients with cancer. Many people with cancer (about 60%) have trouble sleeping, which can lower their quality of life. Sleep disturbance is defined as difficulty initiating or maintaining sleep, waking up earlier than desired and being unable to fall back to sleep, and excessive daytime sleepiness. In adults with cancer, sleep disturbance may be caused by multiple, often co-occurring factors including diagnosis, type, and stage of cancer, treatment regimen, physical complaints (e.g., pain), and psychological distress. Some patients use cannabis to help with sleep, but its effects are not well understood. Cannabis, which some people call marijuana, refers to the dried leaves, flowers, stems, and seeds of the cannabis sativa L plant. The plant contains at least 125 different cannabinoids, including delta-9 tetrahydrocannabinol (THC). Delta-9 THC is the most abundant form of THC in the cannabis plant. It has intoxicating effects, meaning it can temporarily alter a person's mood, thoughts, and perceptions (a \"high\"). This study will help researchers learn how cannabis affects sleep and quality of life compared to usual care.",[27,56],{"date":181,"type":32},{"date":301,"type":21},{"date":167,"type":21},{"name":339,"class":39},"Theodore Brasky PhD",{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":22,"phases":348,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":366},"100492388","phase-1-testing-the-combination-of-the-anti-cancer-drugs-temozolomide-and-m1774-to-evaluate-their-safety-and-effectiveness-100492388","NCT05691491","Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness","A Phase 1\u002F2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774","Inclusion Criteria:\n\n* Patients must have histologically or cytologically confirmed diagnosis of metastatic advanced cancer.\n* In dose escalation, any solid tumor patients with either O6-methylguanine DNA methyltransferase (MGMT) promoter hypermethylation positivity on testing \u002F pre-screening of archival tissue OR an extracranial solid tumor where TMZ is considered a standard of care per National Comprehensive Cancer Network (NCCN) guidelines (neuroendocrine tumor, small cell lung cancer, melanoma or soft tissue sarcoma). The tumor lesion must be safely accessible to a mandatory biopsy. Patients with MGMT promoter hypermethylated colorectal cancer must be mismatch repair proficient \u002F microsatellite stable.\n* In phase 2, only patients with mismatch repair proficient \u002F microsatellite stable colorectal cancer that have MGMT promoter hypermethylation positivity on pre-screening of archival tissue will be eligible.\n* In dose escalation, patients must have progressed after treatment with all available therapies including immunotherapies for metastatic disease that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment. Patients may not have previously received temozolomide or an ataxia telangiectasia and rad3-related (ATR) inhibitor.\n* For patients with mismatch repair proficient \u002F microsatellite stable colorectal cancer in the phase 2 portion, patients must have received prior therapy with 1 or more systemic therapies in the metastatic setting that includes 5-fluorouracil, irinotecan, and oxaliplatin. Patients with microsatellite stable colorectal cancer (mCRC) need to have had exposure, unless contraindicated, to all 3 of oxaliplatin, irinotecan, and fluoropyrimidine (FP).\n\nThe use of 5-fluorouracil and oxaliplatin in the adjuvant setting is acceptable, provided the development of metastatic disease was less than 6 months after the completion of adjuvant therapy.\n\nPatients with a prior hypersensitivity reaction to oxaliplatin in the adjuvant setting do not require retreatment in the metastatic setting.\n\n* Age \\>=18 years. Because no dosing or adverse event data are currently available on the use of M1774 in combination with temozolomide in patients \\\u003C 18 years of age, children are excluded from this study.\n* Measurable disease on CT and\u002For MRI per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria.\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 2 (or Karnofsky \\>= 60%).\n* Hemoglobin \\>=10 g\u002FdL (No blood transfusions are allowed within 14 days of cycle 1 day 1 \\[C1D1\\]).\n* White blood cells (WBC) \\> 3 x 10\\^9\u002FL.\n* Absolute neutrophil count \\>= 1,500\u002FmcL.\n* Platelets \\>= 100,000\u002FmcL.\n* Total bilirubin =\\\u003C 1.5 x institutional upper limit of normal (ULN).\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])\u002Falanine-aminotransferase (ALT) (serum glutamic-pyruvic transaminase \\[SGPT\\]) =\\\u003C 3 x institutional ULN except for when liver metastases are present, in which case they must be =\\\u003C 5 x institutional ULN.\n* Glomerular filtration rate (GFR) \\>= 60 mL\u002Fmin\u002F1.73 m\\^2.\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression for 4 weeks.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.\n* The effects of M1774 on the developing human fetus are unknown. For this reason and because ATR inhibitors agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 6 months after completion of M1774 administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of M1774 administration.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> grade 1) with the exception of alopecia and neuropathy, which may be =\\\u003C grade 2.\n* History of allergic reactions or hypersensitivity attributed to compounds of similar chemical or biologic composition to M1774 or temozolomide, including dacarbazine.\n* Patients with uncontrolled intercurrent illness.\n* Pregnant women are excluded from this study because M1774 is an ATR inhibiting agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with M1774 breastfeeding should be discontinued if the mother is treated with M1774. These potential risks also apply to temozolomide.\n* Patients with a prior history of ataxia telangiectasia.\n* Patients who are not able to swallow orally administered medication or have gastrointestinal disorders likely to interfere with absorption of the study medication.\n* Patients who cannot discontinue proton-pump inhibitors (PPIs) while taking M1774. H-2 receptor antagonists are allowed but should not be taken within 12 hours before or 2 hours after M1774. Antacids are also allowed, but should not be taken 2 hours before 2 hours after M1774.\n* Extensive RT involving greater than 30% of the bone marrow is not permitted during the study.\n* A Fridericia's correction formula (QTcF) \\> 480 ms is exclusionary given the potential for QT.",{"count":20,"type":21},[24,159],"This phase I\u002FII trial studies the side effects and best dose of temozolomide and M1774 and how well they works in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and may have spread to nearby tissue, lymph nodes, or distant parts of the body (advanced). Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells and slow down or stop tumor growth. M1774 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Adding M1774 to temozolomide may shrink or stabilize cancer for longer than temozolomide alone.",[351,352,27,353,354,355,356],"Advanced Malignant Solid Neoplasm","Advanced Microsatellite Stable Colorectal Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Microsatellite Stable Colorectal Carcinoma","Stage III Colorectal Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","2026-06-13",{"date":317,"type":32},{"date":360,"type":32},"2023-09-28",{"date":362,"type":21},"2027-03-01",{"name":364,"class":365},"National Cancer Institute (NCI)","NIH",23,{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":22,"phases":375,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":382,"leadSponsor":384,"locationsCount":40},"100634869","a-spiritual-health-intervention-path-for-improving-spiritual-religious-and-emotional-distress-in-cancer-patients-100634869","NCT07545291","A Spiritual Health Intervention (PATH) for Improving Spiritual, Religious and Emotional Distress in Cancer Patients","Personal Archetypes Toward Healing (PATH) Trial","Inclusion Criteria:\n\n* Age 18 years of age or older\n* English speaking\n* Able to provide informed consent\n* Current diagnosis of cancer at any stage, engaged in active treatment or surveillance at Fred Hutch Cancer Center\n* Scores of \"Somewhat\" or above on at least 1 item the Religious and Spiritual Struggles scale (RSS-5) (e.g., Somewhat = 3 on a 1-to-5 Likert scale)\n\nExclusion Criteria:\n\n* Non-oncology Fred Hutch patients",{"count":258,"type":21},[52],"This clinical trial tests the feasibility and effectiveness of a spiritual health intervention (Personal Archetypes Toward Healing Trial \\[PATH\\]) for improving spiritual, religious and existential distress in patients with cancer. Many patients with cancer find their diagnosis to elicit challenges to their sense of connection, meaning, and purpose. This distress can significantly impact their quality of life. However, spiritual care interventions are often overlooked. PATH builds on multiple theories and therapeutic practices such as role-playing, archetype psychology, cognitive theory, emotion regulation therapy, and dignity therapy. PATH sessions cover topics such as individuation, intrapersonal meaning and worth, intrapersonal distress and faith, interpersonal distress and faith, and transpersonal distress and faith. The PATH intervention may help cancer patients shift their perspectives and access new insights for working through their spiritual, religious and existential distress.",[27,56],"2026-06-04",{"date":380,"type":32},"2026-06-05",{"date":301,"type":21},{"date":383,"type":21},"2027-03-31",{"name":230,"class":39},{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":22,"phases":394,"briefSummary":395,"conditions":396,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":397,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":40},"100596988","patient-navigation-and-the-planning-advance-care-together-website-to-improve-goals-of-care-conversations-in-hematopoietic-cell-transplant-survivors-impact-hct-trial-100596988","NCT07052630","Patient Navigation and the Planning Advance Care Together Website to Improve Goals of Care Conversations in Hematopoietic Cell Transplant Survivors, IMPACT-HCT Trial","Improving Goals of Care Conversations With Hematopoietic Cell Transplant Survivors (IMPACT - HCT)","Inclusion Criteria:\n\n* Received a transplant for a hematologic malignancy\n* Current age 18 years of age or older\n* Currently 1 to 5 years after HCT\n* Ability to speak and read English\n* Has not completed all advance directives and\u002For had a goals of care (GOC) conversation with their physician\n* Access to the internet (via computer, tablet, or mobile device)\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Uncontrolled psychiatric conditions (confirmed through electronic health record \\[EHR\\] by study staff)",{"count":393,"type":21},40,[52],"This clinical trial evaluates the impact of patient navigation and the Planning Advance Care Together (PACT) website, either alone or in combination with one another, on advanced care planning (ACP) in patients with blood cancers who received a hematopoietic cell transplant (HCT). Engagement in ACP, including having goals of care conversations, improves quality of care at the end of life and supporting this should be included in all cancer survivorship care. Patient navigation is a healthcare service that is designed to guide a patient through the healthcare system and reduce barriers to timely screening follow-up, diagnosis, treatment, and supportive care. PACT is a web-based tool that provides information about ACP, assistance with documents for advanced directives, a supportive network and a forum for discussions about ACP. Patients who engage in ACP are more likely to have higher quality of life at the end of life, receive the care they want, die where they prefer, utilize hospice effectively, and are less likely to receive futile, aggressive care at the end of life. For HCT survivors at ongoing risk of death and other disease-related complications, having a plan in place for care they want is critical. Patient navigation and\u002For the PACT website may improve ACP, including completion of advance care directives and goals of care conversations, in patients with blood cancers who received an HCT.",[27],{"date":380,"type":32},{"date":399,"type":32},"2025-10-21",{"date":401,"type":21},"2026-10-31",{"name":230,"class":39},{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":410,"targetDuration":4,"studyType":22,"phases":412,"briefSummary":413,"conditions":414,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":98},"100578945","phase-2-remdesivir-for-the-treatment-of-upper-respiratory-tract-infection-due-to-rsv-in-immunocompromised-individuals-100578945","NCT06817889","Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals","An Open-Label Study to Assess the Safety and Efficacy of Remdesivir for Treatment of Symptomatic Laboratory-Confirmed Respiratory Syncytial Virus Infection of the Upper Respiratory Tract in Patients Receiving Cellular or Bispecific Antibody Therapies","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* Willing and able to provide written informed consent, or with a legal representative who can provide informed consent (where locally approved)\n* RSV confirmed by local lab testing via nucleic acid amplification test (e.g. polymerase chain reaction \\[PCR\\] or respiratory viral panel \\[RVP\\]) using an upper respiratory tract sample collected within the 5 days prior to day 1 (RDV dosing)\n* Symptomatic RSV infection of the upper respiratory tract, with symptom onset and positive microbiologic testing within the 5 days prior to day 1 (RDV dosing). Symptomatic RSV infection is defined as having new upper respiratory symptom(s) or worsening of a pre-existing upper respiratory symptom (if chronic and associated with a previously existing diagnosis, such as chronic lung disease, chronic rhinorrhea, or seasonal allergies)\n* Receiving treatment for a refractory or relapsed hematologic malignancy, or received a hematopoietic cell transplant (HCT), chimeric antigen receptor T cell therapy (CARTx), or bispecific antibody (bsAb) therapy within the past 365 days (relative to RSV diagnosis date)\n* Categorized as moderate-risk (overall score 3-6) or high-risk (overall score 7-10) per an adapted version of the Immunodeficiency Scoring Index (ISI) for RSV, as below, relative to the day of RSV diagnosis:\n\n  * 1 point:\n\n    * Recent (within the prior 30 days) allogeneic HCT, autologous HCT, or CARTx\n    * Corticosteroids within the prior 30 days for management of graft versus host disease (GVHD) or cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).\n  * 2 points:\n\n    * Age ≥ 40 years\n  * 3 points:\n\n    * Absolute neutrophil count (ANC) \\\u003C 500 cells\u002FμL within the prior 7 days\n    * Absolute lymphocyte count (ALC) \\\u003C 200 cells\u002FµL within the prior 7 days\n* Oxygen saturation (SpO2) 93% or greater on room air and at rest (to be measured after participant has rested in a quiet room for ≥ 2 minutes, with oxygen \\[O2\\] saturation probe on finger or earlobe for ≥ 1 minute, with saturation reading remaining ≥ 93%) at screening\n* Willingness to take study drug and complete necessary study procedures\n* Participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception as described\n\nExclusion Criteria:\n\n* Received or receiving an approved or authorized direct-acting antiviral therapy with potential efficacy against RSV (e.g. ribavirin) for ≥ 24 hours within the prior 7 days, and\u002For expected to receive anti-RSV direct-acting antiviral therapies for RSV during the course of the study at the time of screening\n* Received or receiving investigational direct-acting antiviral therapies against RSV for the current RSV episode\n* Received any investigational anti-RSV monoclonal antibodies or off-label use of approved anti-RSV monoclonal antibodies within \\\u003C 4 months or \\\u003C 5 half-lives, whichever is longer, before screening, or expected to receive anti-RSV monoclonal antibodies during the course of the study at the time of screening\n* Received an RSV vaccine after cellular therapy or after starting the current antitumor therapeutic regimen\n* Participation in any other concurrent clinical trial of an experimental treatment for RSV, including RSV vaccines\n* Alanine aminotransferase (ALT) ≥ 5 times the upper limit of normal within 7 days prior to screening\n* Unable to tolerate nasal sampling required for this study, as determined by the investigator (e.g., history of significant epistaxis, nasopharyngeal anatomical abnormalities, nasal or sinus surgery)\n* A life expectancy of three months or less, as determined by the investigator\n* Pregnant, as determined by a Point-of-Care urine pregnancy test or reported by the patient or their electronic health record within 7 days of screening\n* Receiving, requiring, or expected to require supplemental oxygen for RSV-related illness or SpO2 \\\u003C 93% at rest \\\u003C 24 hours prior to study drug administration\n* Previous infection or treatment for RSV, or previous treatment or hospitalization for another respiratory viral infection, \\\u003C 28 days before screening\n* Documented positive test for other respiratory viruses concomitantly (limited to influenza, parainfluenza, adenovirus, human metapneumovirus, or coronavirus \\[including SARS-CoV-2\\]) ≤ 7 days prior to screening, as determined by local testing (additional testing not required)\n* Clinically significant bacteremia or fungemia ≤ 7 days prior to screening and not adequately treated, as determined by the investigator\n* Clinically significant bacterial, fungal, or viral pneumonia within two (2) weeks prior to screening and not adequately treated, as determined by the investigator\n* Clinically significant symptoms of CRS or ICANS within the prior 72 hours before screening that is not adequately controlled, as determined by the investigator\n* Any inability to take study drug or comply with study procedures that, in the opinion of the investigator, would make the participant unsuitable for the study\n* Known hypersensitivity or allergy to the study drug, its metabolites, or formulation excipients",{"count":411,"type":21},60,[159],"This phase II trial tests how well remdesivir works for treatment of respiratory syncytial virus (RSV) infection of the upper respiratory tract in patients receiving cellular or bispecific antibody therapy. Cellular or bispecific antibody therapies cause suppression of the immune system, making infections more frequent and reducing the body's ability to fight the infections. RSV infections are one of the most common respiratory infections in immunocompromised individuals and can cause significant pneumonia and even death. Remdesivir is in a class of medications called antivirals. It works by stopping viruses from spreading in the body.",[27,415,416],"Autoimmune Disease","Respiratory Syncytial Virus Infection","2026-06-01",{"date":419,"type":32},"2026-06-03",{"date":421,"type":32},"2025-12-23",{"date":423,"type":21},"2027-11-30",{"name":230,"class":39},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":432,"targetDuration":4,"studyType":22,"phases":434,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":445,"locationsCount":40},"100618793","phase-2-group-retreat-psilocybin-therapy-for-the-treatment-of-anxiety-and-depression-in-patients-with-metastatic-solid-tumors-or-incurable-hematologic-malignancies-100618793","NCT07336238","Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies","A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression","Inclusion Criteria:\n\n* A diagnosis of metastatic solid tumor, or incurable hematologic malignancy that has been accepted by a physician in a medical record\n* Measurable disease is not required\n* Previous treatment with chemotherapy: There are no minimum or maximum prior lines of chemotherapy\n* 18-85 years of age\n* Required performance status, including the appropriate scale. Eastern Cooperative Oncology Group (ECOG) 0-2\n* Hematocrit \\> 20\n* Platelets (plt) \\> 20K\n* Liver function tests 1.5 x normal\n* Creatinine 1.5 x normal\n* Subjects of childbearing potential must be willing to use an effective contraceptive method from study enrollment until at least 1 month after receiving the investigational agent(s)\n* Must be at least 4 weeks after surgery or radiotherapy at study entry, but can be receiving oral or intravenous (IV) chemotherapy if those schedules can be adjusted around the medication session date\n* Motivated to participate in a group study and able in the research team's judgment to participate in the small group effectively\n* On pre-enrollment screening tests, they will have clinically significant anxiety or depressive symptoms as defined by a score of 11 or greater on the Hospital and Anxiety Depression Scale-Anxiety (HADS)-total\n* English speaking - able to understand the process of consent and the risk and benefits associated with the study, and able to give written informed consent. This is a phase 2a study, and if future larger studies are designed, consideration will be given for non-english-speaking subjects\n* Must be willing to sign a medical release for the investigators to communicate directly with their treating clinicians (mental health professional or oncologist) and doctors to confirm a medication and\u002For medical history\n* Must provide at least one adult who is in contact with the participant at least once a day when the participant is at home who is able to verbally monitor participant-reported changes in their behavior and able to notify research staff of behavior changes that may require research staff assessment\n* Must provide a review of any antidepressant (such as selective serotonin reuptake inhibitor (\\[SSRI)\\], serotonin and norepinephrine reuptake inhibitor \\[SNRI\\]) use\n* Must avoid taking any psychiatric medications or starting a new psychiatric medication during the study. Should participant's doctor recommend starting a new psychiatric medication, participant will be required to notify the study team and the subject would withdraw from the study. (Use of as needed \\[prn\\] benzodiazepines is allowed but high dose chronic benzodiazepine use must be reviewed by the principal investigator \\[PI\\]. Use of prn gabapentoids is allowed but high dose chronic gabapentoid use must be reviewed by the PI.)\n* Must provide a contact (relative, spouse, close friend, or other caregiver) who is willing and able to be reached by the research team in the event that the participant becomes suicidal\n* If the potential participant is of childbearing potential, they must have a negative pregnancy test at baseline and prior to the medication dosing session, and must agree to use highly effective birth control. Highly effective birth control is defined as birth control methods, alone or in combination, that result in a low failure rate (i.e., less than 1 percent per year, which does NOT include condoms or abstinence\n* Are willing to commit to preparation sessions, medication dosing sessions, integration sessions, to complete evaluation instruments and commit to be contacted for all necessary telephone contacts\n\nExclusion Criteria:\n\n* Brain metastases that have not been treated\n* Uncontrolled or concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Pregnancy, breastfeeding, or expecting to conceive or father children for the duration of the trial through 30 days after receipt of investigational agent(s)\n* Personal or immediate family history of schizophrenia, bipolar affective disorder, delusion disorder, paranoid disorder, or schizoaffective disorder\n* Suicidal ideation with a Columbia-Suicide Severity Rating Scale (C-SSRS) measurement of 'low risk' or no risk\n* Current substance abuse disorder (although prospective subjects will not be excluded for reasonable alcohol use that does not meet criteria for alcohol use disorder or marijuana use that does not meet criteria for substance use disorder)\n* Unstable neurological or medical condition; history of seizure, chronic\u002Fsevere headaches\n* Any use of psychedelic drugs in high doses (psilocybin \\> 2 grams of dried mushrooms, lysergic acid diethylamide \\[LSD\\] \\> 200 micrograms) within the prior 3 months (microdosing will not require exclusion but participants would have to agree to discontinue microdosing 1 month before study entry)\n* Use of tramadol, due to the potential for serotonin syndrome with concomitant use of psilocybin\n* Individuals who are on MAOI (monoamine oxidase inhibitors) or who have a known sensitivity to the drug or its metabolites. Psilocybin is contraindicated in medications that are known UDP-glucuronosyltransferase (UGT) enzyme modulators\n* Baseline prolongation of QT\u002Fcorrected QT (QTc) interval (e.g., demonstration on a 12-lead electrocardiogram \\[ECG\\] of a QTc interval \\> 450 milliseconds \\[ms\\])\n* A history of additional risk factors for Torsade de Points (including but not limited to: heart failure, hypokalemia, family history of Long QT Syndrome)\n* The use of concomitant medications that prolong the QT\u002FQTc interval\n* Any history of cardiovascular disease such as history of myocardial infarction or congestive heart failure or cardiac arrhythmia\n* Concomitant use of efavirenz (an antiviral) which cannot be tapered\n* Concomitant use of serotonin-acting supplements due to their potential for interaction with psilocybin, including 5-HTP, St John's Wort, and 'brain food' supplements",{"count":433,"type":21},18,[159],"This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.",[437,438,27,353],"Anxiety","Depression","2026-05-27",{"date":441,"type":32},"2026-05-29",{"date":443,"type":32},"2026-05-19",{"date":167,"type":21},{"name":446,"class":39},"University of Washington",{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":73,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":22,"phases":456,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":98},"100603814","telephone-based-coaching-sessions-tac-to-improve-advance-care-planning-participation-in-advanced-cancer-patients-and-their-support-person-100603814","NCT07141407","Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person","Community-Engaged Pilot Testing of Talking About Cancer (TAC) to Improve Engagement in Advance Care Planning","Inclusion Criteria:\n\n* PATIENT: Current diagnosis of stage III or IV cancer\n* PATIENT: Able to provide informed consent\n* PATIENT: Fluent in English or Spanish\n* PATIENT: Have access to a telephone, computer, or mobile device\n* CAREGIVER (SUPPORT PERSON): Person patient indicates provides support\n* CAREGIVER (SUPPORT PERSON): English or Spanish speaking\n* CAREGIVER (SUPPORT PERSON): 18 years of age or older\n* CAREGIVER (SUPPORT PERSON): Able to provide informed consent\n\nExclusion Criteria:\n\n* PATIENT: Too ill or weak to complete the interviews (as judged by the interviewer)\n* PATIENT: Receiving hospice at the time of enrollment\n* PATIENT: Younger than age 18",{"count":455,"type":21},80,[52],"This clinical trial studies whether telephone-based coaching sessions, Talking About Cancer (TAC), work to improve engagement in advance care planning (ACP) in patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and their support person. Participation in ACP, which includes having end of life (EOL) care conversations and completing advance directives (e.g., living will, health care proxy, do not resuscitate order), improves quality EOL care. Despite this, less than half of patients with advanced cancer have EOL care conversations or complete advance directives. TAC coaching sessions are delivered by a social worker over the phone. They are designed to help patients and their support person communicate about ACP, manage the distress these conversations can cause, and participate in the process of ACP with a clear action plan of having goals-of-care conversations and completing advance directives. This may be an effective way to improve ACP participation in advanced cancer patients and their support person.",[351,27],{"date":441,"type":32},{"date":461,"type":32},"2026-04-08",{"date":463,"type":21},"2026-12-14",{"name":230,"class":39},{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":276,"phases":4,"briefSummary":474,"conditions":475,"keywords":476,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":40},"100583786","investigating-memory-and-physical-activity-after-cancer-treatment-in-survivors-of-adolescent-and-young-adult-cancers-100583786","NCT06880861","Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers","IMPACT","Inclusion Criteria:\n\n* Adults (aged 18+ years)\n* Primary diagnosis of cancer when 15-39 years-old\n* Access to a desktop computer or laptop with reliable internet access\n* No gross motor impairments that prohibit ambulation\n* Willing to complete study requirements\n* English speaking\n\nExclusion Criteria:\n\n* Diagnosed with nonmelanoma skin cancer only\n* Not diagnosed with cancer in adolescent and young adult (AYA) age range of 15-39 years\n* Scheduled travel during the study period that is not indicative of individual's normal schedule",{"count":473,"type":21},100,"This study evaluates relationships among physical activity, thinking, and memory after cancer treatment in survivors of adolescent and young adult cancers.",[27,56],[477,478,479,480,481,482,483],"cancer","adolescent","young adult","cognition","memory","exercise","physical activity","2026-05-26",{"date":486,"type":32},"2026-05-28",{"date":488,"type":32},"2025-07-01",{"date":490,"type":21},"2026-09-30",{"name":249,"class":39},{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":4,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":22,"phases":501,"briefSummary":502,"conditions":503,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":504,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":40},"100571652","acupressure-for-the-reduction-of-anxiety-in-patients-receiving-cancer-directed-therapy-100571652","NCT06723041","Acupressure for the Reduction of Anxiety in Patients Receiving Cancer-Directed Therapy","Acupressure for Anxiety: A Randomized Controlled Trial of an Acupressure Intervention for Patients Receiving Cancer-Directed Therapy","Inclusion Criteria:\n\n* NURSE-LED INTERVENTION: Age \\>= 18 years and be diagnosed with cancer\n* NURSE-LED INTERVENTION: Undergoing systemic, antineoplastic therapy\n* NURSE-LED INTERVENTION: Ability to provide oral consent\n* NURSE-LED INTERVENTION: Willingness to undergo a nurse-led acupressure intervention\n* NURSE-LED INTERVENTION: Willingness and ability to complete pre- and post-intervention questionnaires in English\n* NURSE-LED INTERVENTION: Report acute anxiety as a 5 or higher on a scale for 0 (no anxiety) to 10 (severe anxiety)\n* SELF-ADMINISTRATION INTERVENTION: Age \\>= 18 years and be diagnosed with cancer\n* SELF-ADMINISTRATION INTERVENTION: Undergoing systemic, antineoplastic therapy\n* SELF-ADMINISTRATION INTERVENTION: Ability to provide oral consent\n* SELF-ADMINISTRATION INTERVENTION: Willingness to undergo a nurse-led acupressure intervention\n* SELF-ADMINISTRATION INTERVENTION: Willingness and ability to complete pre- and post-intervention questionnaires in English\n* SELF-ADMINISTRATION INTERVENTION: Report acute anxiety as a 5 or higher on a scale for 0 (no anxiety) to 10 (severe anxiety)\n* SELF-ADMINISTRATION INTERVENTION: Reports 2+\u002Fday anxiety episodes at home\n* SELF-ADMINISTRATION INTERVENTION: Interested in learning self-administered acupressure\n\nExclusion Criteria:\n\n* Prior experiences with acupressure, or training in acupressure points",{"count":500,"type":21},78,[52],"This clinicaI trial is being done to determine if acupressure is helpful to reduce anxiety related to chemotherapy, compared with \"sham\" (or placebo) acupressure in patients with cancer. Anxiety, experienced by many patients with cancer, can be related to chemotherapy and may contribute to other symptoms, such as nausea and poor quality of life. Some patients diagnosed with cancer express interest in non-medicine ways to manage symptoms. Acupressure is the application of non-invasive finger pressure along energy points throughout the body in order to relieve pain and induce a feeling of well-being. Previous research has shown that acupressure can help both adults and children with their anxiety in certain situations, such as after surgery. Patients can be taught how to do the acupressure on themselves, making this an intervention that can be done anywhere. Acupressure is well tolerated with minimal reports of adverse reactions. Undergoing acupressure may be effective in reducing anxiety in cancer patients receiving chemotherapy.",[27,56],{"date":486,"type":32},{"date":506,"type":32},"2024-12-11",{"date":508,"type":21},"2028-12-31",{"name":249,"class":39},{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":22,"phases":518,"briefSummary":519,"conditions":520,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":40},"100640389","a-wearable-biosensor-patch-for-non-invasive-monitoring-for-patients-undergoing-abdominal-or-chest-surgery-100640389","NCT07612085","A Wearable Biosensor Patch for Non-Invasive Monitoring for Patients Undergoing Abdominal or Chest Surgery","Pilot Study on the Clinical Application of a Wearable Biosensor Patch for Non-Invasive Measurement of Biochemical and Blood Gas Analytes","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Scheduled to have an elective abdominal or thoracic operation with anticipated post-operative hospitalization ≥ 3 days\n* Willingness to provide sweat samples, complete surveys, and permit review of medical records for research use\n* Ability to consent to the study procedures\n\nExclusion Criteria:\n\n* Carbachol or pilocarpine allergy\n* Adhesive\u002Ftape allergy\n* Damaged or irritated skin on one or both wrists that prohibits placement of the biosensor and sweat collecting devices\n* Pregnant women\n* Children less than 18 years of age",{"count":258,"type":21},[52],"This clinical trial tests the feasibility and safety of a wearable biosensor patch for non-invasive monitoring for patients undergoing abdominal or chest surgery. Wearable biosensor patches have been developed by researchers to provide a non-invasive way to monitor substances that are normally checked using blood tests. This may reduce the need for frequent blood draws. The patches use gentle electrical stimulation to produce sweat and tiny built-in sensors to measure substances such as glucose, creatinine, and markers of inflammation, as well as oxygen and carbon dioxide levels. The wearable biosensor patch may be a feasible and safe way to monitor patients undergoing abdominal or chest surgery.",[27,56],"2026-05-21",{"date":486,"type":32},{"date":524,"type":21},"2026-09-02",{"date":526,"type":21},"2027-04-15",{"name":38,"class":39}]